By enGenes Biotech…
To get in touch with enGenes Biotech GmbH, simply fill out the form below.
Subscribe to Supplier
enGenes Biotech to make debut at Swiss Biotech Day conference
Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) will make its debut at the upcoming annual Swiss Biotech Day conference in Basel.
The first appearance of enGenes at this central event in Europe’s biotech industry calendar underlines the increasing importance of its leading-edge upstream and downstream process development technologies to Switzerland’s biotechnology hub.
Global Village networking
The enGenes team at the Congress Center in Basel will be led by its CEO, Dr. Jürgen Mairhofer and Head of Business Development, Dr. Karl Hübler. They will use the conference’s Global Village and many other networking opportunities to showcase the contribution that its proprietary high-yield biomolecules production platform enGenes -eXpress can make to the economics of all sorts of biotech projects (biopharma and industrial biotech).
“We are very pleased to be able to join the Swiss Biotech Association and guests from around the world to mark the tenth anniversary of this event that has become so important to our industry,” said Dr. Mairhofer.
Enhanced yield expression
“Our services have become increasingly important for the Swiss Biotech industry and we will seek to find new partners for process development projects and small scale production that can leverage the enhanced yields achievable by using our E. coli based -eXpress technology with its protein secretion into the cell free supernatant,” added Dr. Mairhofer.
Dr. Hübler commented: “We can also demonstrate the contribution of our auxiliary know-how in upstream- and downstream-processing, such as our innovative bioconjugation solution that can specifically modify recombinant proteins and achieve site-specific incorporation of non-canonical amino acids or our plasmid DNA production platform that enables significant cost savings when manufacturing e.g. viral vectors”.
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes -eXpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes -eXpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
About Swiss Biotech Days 2023
Celebrating its tenth anniversary, the Swiss Biotech Day conference has become a leading annual event for the European biotechnology community, exploring trends and latest developments in R&D, manufacturing, data management, artificial intelligence and innovative financing.
The conference is built around the Annual General Assembly of the Swiss Biotech Association but also draws in entrepreneurs, investors, researchers, analysts, political decision makers and industry stakeholders from around the world, with more than 1,100 participants attending last year’s event.
Swiss Biotech Day for 2023 will actually extend over one and half days, opening April 24 at the Basel Conference Center and again offering high-level experts from the life sciences industry the space and the time to network, discuss and discover In addition, it will feature a “Global Village” of round table discussions providing opportunities for cross-border investments, public-private partnerships, research and development collaborations and knowledge exchange, along with one-to-one networking.
The event is organized by the Swiss Biotech Association in partnership with BIOCOM AG, with further information at: https://swissbiotechday.ch
Click on Partnering with enGenes for further information.